Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
05. November 2024 07:30 ET
|
Minerva Neurosciences, Inc
Minerva Neurosciences (Nasdaq: NERV) today reported business updates and financial results for the third quarter of 2024 ending September 30, 2024.
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
06. August 2024 07:30 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
01. Mai 2024 07:30 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
27. Februar 2024 08:00 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
22. Februar 2024 07:00 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
07. November 2023 07:30 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
01. August 2023 07:30 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
28. Juni 2023 08:30 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
15. Mai 2023 07:30 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
10. Mai 2023 08:00 ET
|
Minerva Neurosciences, Inc
FDA confirms acceptance of the filing of the NDA for roluperidone Application has been granted a standard review FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 26,...